Orca Biosystems, Inc.
Privately held: no public share price
Assets
(2 total)
2Total Assets
1Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
Orca-T(TREGZI) | Approved | Allogeneic engineered T-cell immunotherapyCell therapy | Acute Myeloid Leukemia |
| Phase 1/2 | Treg-enriched allogeneic haematopoietic stem cell graftCell therapy | Acute Myeloid Leukemia |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
November 2027 (1)
Orca-T · TREGZIPhase 2Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia
Est. primary completion 2027-11 · NCT07216443 · CT.gov ↗
What to watch
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
No financial reports recorded.